Annals of Surgical Oncology

, Volume 24, Issue 6, pp 1731–1738 | Cite as

Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer

  • John R. Bergquist
  • Tommy Ivanics
  • Christopher R. Shubert
  • Elizabeth B. Habermann
  • Rory L. Smoot
  • Michael L. Kendrick
  • David M. Nagorney
  • Michael B. Farnell
  • Mark J. Truty
Pancreatic Tumors
  • 240 Downloads

Abstract

Introduction

Adjuvant chemotherapy improves survival after curative intent resection for localized pancreatic adenocarcinoma (PDAC). Given the differences in perioperative morbidity, we hypothesized that patients undergoing distal partial pancreatectomy (DPP) would receive adjuvant therapy more often those undergoing pancreatoduodenectomy (PD).

Methods

The National Cancer Data Base (2004–2012) identified patients with localized PDAC undergoing DPP and PD, excluding neoadjuvant cases, and factors associated with receipt of adjuvant therapy were identified. Overall survival (OS) was analyzed using multivariable Cox proportional hazards regression.

Results

Overall, 13,501 patients were included (DPP, n = 1933; PD, n = 11,568). Prognostic characteristics were similar, except DPP patients had fewer N1 lesions, less often positive margins, more minimally invasive resections, and shorter hospital stay. The proportion of patients not receiving adjuvant chemotherapy was equivalent (DPP 33.7%, PD 32.0%; p = 0.148). The type of procedure was not independently associated with adjuvant chemotherapy (hazard ratio 0.96, 95% confidence interval 0.90–1.02; p = 0.150), and patients receiving adjuvant chemotherapy had improved unadjusted and adjusted OS compared with surgery alone. The type of resection did not predict adjusted mortality (p = 0.870).

Conclusion

Receipt of adjuvant chemotherapy did not vary by type of resection but improved survival independent of procedure performed. Factors other than type of resection appear to be driving the nationwide rates of post-resection adjuvant chemotherapy in localized PDAC.

Keywords

Overall Survival Pancreatic Cancer Adjuvant Chemotherapy Adjuvant Therapy National Cancer Data Base 

Notes

Acknowledgment

The NCDB is a joint project of the CoC of the American College of Surgeons and the American Cancer Society. The data used are derived from a de-identified NCDB PUF. The American College of Surgeons and the CoC have not verified and are not responsible for the analytic or statistical methods or the conclusions drawn from these data by the investigators. The authors gratefully acknowledge the support of the Mayo Clinic Department of Surgery and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery as substantial contributors of resources to the project. Additionally, Dr. Bergquist acknowledges the support of the Mayo Clinic Clinician Investigator Training Program for salary support. Finally, we would like to thank the Society for Surgery of the Alimentary Tract for affording us the opportunity to present this work at their annual Digestive Disease Week in San Diego, CA, USA, in May 2016.

Grant Support

The Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery provides salary support for Dr. Habermann and in kind material support for Drs. Bergquist and Shubert. In addition, Drs. Bergquist and Shubert have received salary support from the Mayo Clinic Clinician Investigator Training program.

Supplementary material

10434_2016_5762_MOESM1_ESM.docx (32 kb)
Supplemental Figure 1: STROBE Diagram of Cohorts Included and Excluded. Supplementary material 1 (DOCX 32 kb)

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27(17):2855–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2008;247(3):456–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633, discussion 633–636.Google Scholar
  5. 5.
    Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang H, Ramakrishnan A, Fletcher S, Prochownik EV, Genetics M. Early vs. late chemoradiation therapy and the postoperative interval to adjuvant therapy do not correspond to local recurrence in resected pancreatic cancer. Pancreat Discord Ther. 2015;5(2): pii: 151.Google Scholar
  7. 7.
    Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer. 2009;100(2):246–50.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12.CrossRefPubMedGoogle Scholar
  13. 13.
    Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. Ann Surg. 2014;260(2):244–51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Birkmeyer JD, Dimick JB, Staiger DO. Operative mortality and procedure volume as predictors of subsequent hospital performance. Ann Surg. 2006;243(3):411–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kim C, Owen D, Gill S. Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. Am J Clin Oncol. 2012;35(3):212–5.CrossRefPubMedGoogle Scholar
  17. 17.
    McMillan MT, Christein JD, Callery MP, Behrman SW, Drebin JA, Hollis RH, et al. Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy. Surgery. 2016;159(4):1013–22.CrossRefPubMedGoogle Scholar
  18. 18.
    He J, Pawlik TM, Makary MA, Wolfgang CL, Weiss MJ. Laparoscopic pancreatic surgery. Minerva Chir. 2014;69(6):371–8.PubMedGoogle Scholar
  19. 19.
    Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg. 2012;255(6):1048–59.CrossRefPubMedGoogle Scholar
  20. 20.
    Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21(9):2873–81.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Parikh P, Shiloach M, Cohen ME, Bilimoria KY, Ko CY, Hall BL, et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB (Oxford). 2010;12(7):488–97.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pitt HA, Kilbane M, Strasberg SM, Pawlik TM, Dixon E, Zyromski NJ, et al. ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford). 2009;11(5):405–13.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kneuertz PJ, Pitt HA, Bilimoria KY, Smiley JP, Cohen ME, Ko CY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg. 2012;16(9):1727–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using the NCDB for cancer care improvement: An introduction to available quality assessment tools. J Surg Oncol. 2009;99(8):488–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Abraham A, Al-Refaie WB, Parsons HM, Dudeja V, Vickers SM, Habermann EB. Disparities in pancreas cancer care. Ann Surg Oncol. 2013;20(6):2078–87.CrossRefPubMedGoogle Scholar
  30. 30.
    Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014;156(2):280–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Lim K-H, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192–200.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer. 2010;116(7):1681–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Artinyan A, Anaya DA, McKenzie S, Ellenhorn JDI, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117(10):2044–9.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • John R. Bergquist
    • 1
    • 2
  • Tommy Ivanics
    • 1
    • 2
  • Christopher R. Shubert
    • 1
    • 2
  • Elizabeth B. Habermann
    • 2
  • Rory L. Smoot
    • 1
  • Michael L. Kendrick
    • 1
  • David M. Nagorney
    • 1
  • Michael B. Farnell
    • 1
  • Mark J. Truty
    • 1
  1. 1.Division of Hepatobiliary Surgery, Section of Subspecialty General Surgery, Department of SurgeryMayo ClinicRochesterUSA
  2. 2.Robert D. and Patricia E. Kern Center for the Science of Health Care DeliveryMayo ClinicRochesterUSA

Personalised recommendations